{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:22:14Z","timestamp":1790544134440,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010661","name":"EC | Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["856620"],"award-info":[{"award-number":["856620"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Studies of survival in hematological malignancies (HMs) have generally shown an improvement over time, although most of these studies are limited by a short follow-up period. Using the NORDCAN database with data from Denmark, Finland, Norway and Sweden, we follow periodic increases in relative survival in seven HMs through half a century up to 2015\u20132019. Five-year survival improved in all seven HMs, reaching 90% for Hodgkin lymphoma (HL), myeloproliferative neoplasias and chronic lymphocytic leukemia (CLL), 60% for multiple myeloma (MM) and chronic myeloid leukemias (CMLs), 50% for the myelodysplastic syndromes and 30% for acute myeloid leukemia (AML). Improvements in survival over 50 years ranged from 20% to more than 50% units across the different HMs. The likely reasons for such progress include earlier diagnoses, improved risk stratification and advances in treatment. We observed differing temporal trends in improvements in survival. The gradual increases observed in HL, CLL and AML highlight the impact of optimization of existing therapies and improvements in diagnostics and risk stratification, whereas the rapid increases observed in the CMLs and MM highlight the impact of novel therapies. Recent therapeutic advances may further improve survival in HMs where survival remains low such as in AML.<\/jats:p>","DOI":"10.1038\/s41375-023-01852-w","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T15:03:34Z","timestamp":1677251014000},"page":"854-863","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Survival in hematological malignancies in the Nordic countries through a half century with correlation to treatment"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2769-3316","authenticated-orcid":false,"given":"Kari","family":"Hemminki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne","family":"Hemminki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asta","family":"F\u00f6rsti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6133-0164","authenticated-orcid":false,"given":"Amit","family":"Sud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,24]]},"reference":[{"key":"1852_CR1","doi-asserted-by":"publisher","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","volume":"68","author":"VT DeVita Jr","year":"2008","unstructured":"DeVita VT Jr, Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68:8643\u201353.","journal-title":"Cancer Res"},{"key":"1852_CR2","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/ncponc1186","volume":"5","author":"AM Evens","year":"2008","unstructured":"Evens AM, Hutchings M, Diehl V. Treatment of Hodgkin lymphoma: the past, present, and future. Nat Clin Pract Oncol. 2008;5:543\u201356.","journal-title":"Nat Clin Pract Oncol"},{"key":"1852_CR3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41571-018-0136-6","volume":"16","author":"CH Pui","year":"2019","unstructured":"Pui CH, Nichols KE, Yang JJ. Somatic and germline genomics in paediatric acute lymphoblastic leukaemia. Nat Rev Clin Oncol. 2019;16:227\u201340.","journal-title":"Nat Rev Clin Oncol"},{"key":"1852_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41409-018-0239-9","volume":"54","author":"B Yang","year":"2019","unstructured":"Yang B, Yu R, Cai L, Bin G, Chen H, Zhang H, et al. Haploidentical versus matched donor stem cell transplantation for patients with hematological malignancies: a systemic review and meta-analysis. Bone Marrow Transplant. 2019;54:99\u2013122.","journal-title":"Bone Marrow Transplant"},{"key":"1852_CR5","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3390\/vaccines9060614","volume":"9","author":"M Khan","year":"2021","unstructured":"Khan M, Maker AV, Jain S. The evolution of cancer immunotherapy. Vaccines (Basel). 2021;9:614.","journal-title":"Vaccines (Basel)"},{"key":"1852_CR6","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1016\/j.ejca.2015.08.003","volume":"51","author":"R De Angelis","year":"2015","unstructured":"De Angelis R, Minicozzi P, Sant M, Dal Maso L, Brewster DH, Osca-Gelis G, et al. Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000-2007: results of EUROCARE-5 population-based study. Eur J Cancer. 2015;51:2254\u201368.","journal-title":"Eur J Cancer"},{"key":"1852_CR7","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(14)70282-7","volume":"15","author":"M Sant","year":"2014","unstructured":"Sant M, Minicozzi P, Mounier M, Anderson LA, Brenner H, Holleczek B, et al. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol. 2014;15:931\u201342.","journal-title":"Lancet Oncol"},{"key":"1852_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0323-4","volume":"10","author":"D Pulte","year":"2020","unstructured":"Pulte D, Jansen L, Brenner H. Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century. Blood Cancer J. 2020;10:56.","journal-title":"Blood Cancer J"},{"key":"1852_CR9","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1080\/0284186X.2017.1407039","volume":"57","author":"E Pukkala","year":"2018","unstructured":"Pukkala E, Engholm G, Hojsgaard Schmidt LK, Storm H, Khan S, Lambe M, et al. Nordic Cancer Registries \u2013 an overview of their procedures and data comparability. Acta Oncol. 2018;57:440\u201355.","journal-title":"Acta Oncol"},{"key":"1852_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-96804-8","volume":"11","author":"K Hemminki","year":"2021","unstructured":"Hemminki K, F\u00f6rsti A, Hansson M. Incidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in Sweden up to year 2016. Sci Rep. 2021;11:17272.","journal-title":"Sci Rep"},{"key":"1852_CR11","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3109\/02841861003631495","volume":"49","author":"HH Storm","year":"2010","unstructured":"Storm HH, Klint A, Tryggvadottir L, Gislum M, Engholm G, Bray F, et al. Trends in the survival of patients diagnosed with malignant neoplasms of lymphoid, haematopoietic, and related tissue in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncol. 2010;49:694\u2013712.","journal-title":"Acta Oncol"},{"key":"1852_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00728-z","volume":"12","author":"K Hemminki","year":"2022","unstructured":"Hemminki K, Hemminki J, F\u00f6rsti A, Sud A. Survival trends in hematological malignancies in the Nordic countries through 50 years. Blood Cancer J. 2022;12:150.","journal-title":"Blood Cancer J"},{"key":"1852_CR13","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3109\/02841861003782017","volume":"49","author":"G Engholm","year":"2010","unstructured":"Engholm G, Ferlay J, Christensen N, Bray F, Gjerstorff ML, Klint A, et al. NORDCAN-a Nordic tool for cancer information, planning, quality control and research. Acta Oncol. 2010;49:725\u201336.","journal-title":"Acta Oncol"},{"key":"1852_CR14","unstructured":"Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. p. 351."},{"key":"1852_CR15","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3109\/02841861003801148","volume":"49","author":"HH Storm","year":"2010","unstructured":"Storm HH, Engholm G, Hakulinen T, Tryggvad\u00f3ttir L, Klint A, Gislum M, et al. Survival of patients diagnosed with cancer in the Nordic countries up to 1999-2003 followed to the end of 2006. A critical overview of the results. Acta Oncol. 2010;49:532\u201344.","journal-title":"Acta Oncol"},{"key":"1852_CR16","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1080\/0284186X.2020.1822544","volume":"59","author":"FE Lundberg","year":"2020","unstructured":"Lundberg FE, Andersson TM, Lambe M, Engholm G, M\u00f8rch LS, Johannesen TB, et al. Trends in cancer survival in the Nordic countries 1990-2016: the NORDCAN survival studies. Acta Oncol. 2020;59:1266\u201374.","journal-title":"Acta Oncol"},{"key":"1852_CR17","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/j.ejca.2004.07.007","volume":"40","author":"H Brenner","year":"2004","unstructured":"Brenner H, Arndt V, Gefeller O, Hakulinen T. An alternative approach to age adjustment of cancer survival rates. Eur J Cancer. 2004;40:2317\u201322.","journal-title":"Eur J Cancer"},{"key":"1852_CR18","doi-asserted-by":"publisher","first-page":"e000644","DOI":"10.1136\/bmjgast-2021-000644","volume":"8","author":"K Hemminki","year":"2021","unstructured":"Hemminki K, F\u00f6rsti A, Hemminki A. Survival in colon and rectal cancers in Finland and Sweden through 50 years. BMJ Open Gastroenterol. 2021;8:e000644.","journal-title":"BMJ Open Gastroenterol"},{"key":"1852_CR19","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1002\/ijc.22912","volume":"121","author":"I Turesson","year":"2007","unstructured":"Turesson I, Linet MS, Bjorkholm M, Kristinsson SY, Goldin LR, Caporaso NE, et al. Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003. Int J Cancer. 2007;121:2260\u20136.","journal-title":"Int J Cancer"},{"key":"1852_CR20","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/sj.leu.2402177","volume":"16","author":"K Hemminki","year":"2001","unstructured":"Hemminki K, Jiang Y. Familial polycythemia vera: results from the Swedish Family-cancer Database. Leukemia. 2001;16:1313\u20135.","journal-title":"Leukemia"},{"key":"1852_CR21","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384.","journal-title":"Leukemia"},{"key":"1852_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.canep.2019.01.003","volume":"59","author":"S Benzarti","year":"2019","unstructured":"Benzarti S, Daskalakis M, Feller A, Bacher VU, Schnegg-Kaufmann A, R\u00fcfer A, et al. Trends of incidence and survival of patients with chronic myelomonocytic leukemia between 1999 and 2014: a comparison between Swiss and American population-based cancer registries. Cancer Epidemiol. 2019;59:51\u20137.","journal-title":"Cancer Epidemiol"},{"key":"1852_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-020-00312-3","volume":"20","author":"T Beyer","year":"2020","unstructured":"Beyer T, Bidaut L, Dickson J, Kachelriess M, Kiessling F, Leitgeb R, et al. What scans we will read: imaging instrumentation trends in clinical oncology. Cancer Imaging. 2020;20:38.","journal-title":"Cancer Imaging"},{"key":"1852_CR24","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1002\/jmri.26848","volume":"51","author":"ME Mayerhoefer","year":"2020","unstructured":"Mayerhoefer ME, Archibald SJ, Messiou C, Staudenherz A, Berzaczy D, Sch\u00f6der H. MRI and PET\/MRI in hematologic malignancies. J Magn Reson Imaging. 2020;51:1325\u201335.","journal-title":"J Magn Reson Imaging"},{"key":"1852_CR25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/joim.13508","volume":"292","author":"T W\u00e4sterlid","year":"2022","unstructured":"W\u00e4sterlid T, Cavelier L, Haferlach C, Konopleva M, Fr\u00f6hling S, \u00d6stling P, et al. Application of precision medicine in clinical routine in haematology\u2013challenges and opportunities. J Intern Med. 2022;292:243\u201361.","journal-title":"J Intern Med"},{"key":"1852_CR26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13045-021-01077-3","volume":"14","author":"JZ Hou","year":"2021","unstructured":"Hou JZ, Ye JC, Pu JJ, Liu H, Ding W, Zheng H, et al. Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting. J Hematol Oncol. 2021;14:66.","journal-title":"J Hematol Oncol"},{"key":"1852_CR27","doi-asserted-by":"publisher","first-page":"iv19","DOI":"10.1093\/annonc\/mdy080","volume":"29","author":"DA Eichenauer","year":"2018","unstructured":"Eichenauer DA, Aleman BMP, Andr\u00e9 M, Federico M, Hutchings M, Illidge T, et al. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv19\u2013iv29.","journal-title":"Ann Oncol"},{"key":"1852_CR28","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1023\/A:1008294312741","volume":"8","author":"V Diehl","year":"1997","unstructured":"Diehl V, Sieber M, R\u00fcffer U, Lathan B, Hasenclever D, Pfreundschuh M, et al. BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin\u2019s disease. The German Hodgkin\u2019s Lymphoma Study Group. Ann Oncol. 1997;8:143\u20138.","journal-title":"Ann Oncol"},{"key":"1852_CR29","doi-asserted-by":"publisher","first-page":"ii60","DOI":"10.1093\/annonc\/mdn090","volume":"19","author":"B Eichhorst","year":"2008","unstructured":"Eichhorst B, Hallek M, Dreyling M. Chronic lymphocytic leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19:ii60\u20132.","journal-title":"Ann Oncol"},{"key":"1852_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","volume":"32","author":"B Eichhorst","year":"2021","unstructured":"Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:23\u201333.","journal-title":"Ann Oncol"},{"key":"1852_CR31","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/annonc\/mdp141","volume":"20","author":"M Fey","year":"2009","unstructured":"Fey M, Dreyling M. Acute myeloblastic leukemia in adult patients: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20:100\u20131.","journal-title":"Ann Oncol"},{"key":"1852_CR32","doi-asserted-by":"publisher","first-page":"721","DOI":"10.6004\/jnccn.2019.0028","volume":"17","author":"MS Tallman","year":"2019","unstructured":"Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bixby D, et al. Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2019;17:721\u201349.","journal-title":"J Natl Compr Cancer Netw"},{"key":"1852_CR33","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","volume":"392","author":"NJ Short","year":"2018","unstructured":"Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392:593\u2013606.","journal-title":"Lancet"},{"key":"1852_CR34","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1182\/blood-2008-09-179341","volume":"113","author":"AR Derolf","year":"2009","unstructured":"Derolf AR, Kristinsson SY, Andersson TM, Landgren O, Dickman PW, Bj\u00f6rkholm M. Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Blood. 2009;113:3666\u201372.","journal-title":"Blood"},{"key":"1852_CR35","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/S0140-6736(13)61901-7","volume":"383","author":"L Ad\u00e8s","year":"2014","unstructured":"Ad\u00e8s L, Itzykson R, Fenaux P. Myelodysplastic syndromes. Lancet. 2014;383:2239\u201352.","journal-title":"Lancet"},{"key":"1852_CR36","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.6004\/jnccn.2017.0157","volume":"15","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Jamieson C, Bhatia R, Deininger MW, Fletcher CD, Gerds AT, et al. NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. J Natl Compr Cancer Netw. 2017;15:1193\u2013207.","journal-title":"J Natl Compr Cancer Netw"},{"key":"1852_CR37","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1002\/ijc.33762","volume":"149","author":"K Hemminki","year":"2021","unstructured":"Hemminki K, F\u00f6rsti A, Houlston R, Sud A. Epidemiology, genetics and treatment of multiple myeloma and precursor diseases. Int J Cancer. 2021;149:1980\u201396.","journal-title":"Int J Cancer"},{"key":"1852_CR38","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3324\/haematol.2017.178103","volume":"103","author":"CH Blimark","year":"2018","unstructured":"Blimark CH, Turesson I, Genell A, Ahlberg L, Bj\u00f6rkstrand B, Carlson K, et al. Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry. Haematologica. 2018;103:506\u201313.","journal-title":"Haematologica"},{"key":"1852_CR39","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3816\/CLM.2009.n.056","volume":"9","author":"RA Kyle","year":"2009","unstructured":"Kyle RA, Rajkumar SV. Treatment of multiple myeloma: a comprehensive review. Clin Lymphoma Myeloma. 2009;9:278\u201388.","journal-title":"Clin Lymphoma Myeloma"},{"key":"1852_CR40","doi-asserted-by":"crossref","unstructured":"Bergsagel PL. Where we were, where we are, where we are going: progress in multiple myeloma. Am Soc Clin Oncol Educ Book. 2014:199\u2013203.","DOI":"10.14694\/EdBook_AM.2014.34.199"},{"key":"1852_CR41","doi-asserted-by":"publisher","unstructured":"Turesson I, Bjorkholm M, Blimark CH, Kristinsson S, Velez R, Landgren O. Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival. Eur J Haematol. 2018. https:\/\/doi.org\/10.1111\/ejh.13083.","DOI":"10.1111\/ejh.13083"},{"key":"1852_CR42","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bj\u00f6rkholm M, Dickman PW, H\u00f6glund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851\u20137.","journal-title":"J Clin Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01852-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01852-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01852-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T11:09:23Z","timestamp":1680779363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01852-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,24]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1852"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-01852-w","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,24]]},"assertion":[{"value":"3 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Aggregated data from a publicly accessible database were used posing no ethical issues.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}